Skip to content

Effect of Carnitine Supplementation Additive to Exercise Therapy in Dialysis Patients: A Randomized Controlled Trial

Effect of Carnitine Supplementation Additive to Exercise Therapy in Dialysis Patients: A Randomized Controlled Trial - Effect of Carnitine Supplementation Additive to Exercise Therapy in Dialysis Patients: A Randomized Controlled Trial

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
JPRN
Registry ID
JPRN-UMIN000053894
Enrollment
24
Registered
2024-04-01
Start date
2024-04-01
Completion date
Unknown
Last updated
2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Dialysis patients

Interventions

Intervention: 12-week carnitine supplementation in addition to exercise therapy Exercise training includes 3-5 minutes of stretching followed by 10-30 minutes of aerobic exercise, plus 3-5 minutes
s condition. Control: 12-week exercise therapy only Exercise therapy will be the same as in the intervention group.

Sponsors

International University of Health and Welfare Narita Hospital
Lead Sponsor

Eligibility

Sex/Gender
All

Inclusion criteria

Inclusion criteria: 1) Dialysis outpatients with carnitine deficiency or high risk of carnitine deficiency (free carnitine [FC] < 36 micromol/L) and/or carnitine insufficiency (acylcarnitine [AC]/FC > 0.40) 2) Patients from whom written informed consent was obtained

Exclusion criteria

Exclusion criteria: 1) Patients who are contraindicated for exercise training. Concrete criteria are as follows: patients with uncontrolled persistent hypertension (systolic blood pressure >= 180 mmHg or diastolic pressure >= 110 mmHg); severe anemia (Hb < 7 g/dL); active proliferative diabetic retinopathy; prior symptomatic coronary artery or cerebrovascular diseases within the previous 3 months; uncontrolled heart failure (NYHA >= III); symptomatic or lethal arrhythmia; severe valvular diseases; and walking difficulty due to orthopedic, cerebrovascular and peripheral artery diseases. 2) Unstable dialysis patients. Concrete criteria are as follows: patients who undergo dialysis less than 3 months and those with uncontrolled uremia (BUN > 100 mg/dL, K > 6.0 mEq/L and HCO3 < 18 mmoL/L). 3) Patients deemed inadequate for monitoring during study period, as determined by investigators.

Design outcomes

Primary

MeasureTime frame
VO2peak (peak oxygen uptake) assessed by cardiopulmonary test, evaluated 12 weeks after the assignment

Secondary

MeasureTime frame
The following parameters at 12 weeks after the assignment: VE/VCO2 slope, WR (work rate), AT (anaerobic threshold), and CI (chronotropic index) assessed by cardiopulmonary test Various physical activity levels (including adherence to home exercise therapy) assessed by iAide2 Body composition (including skeletal mass index [SMI]) as assessed by InBody Specific clinical parameters (nutritional status, anemia, carnitine profile, biomarkers of cardiac function, etc.)

Countries

Japan

Contacts

Public ContactKiyotaka Uchiyama

International University of Health and Welfare Narita Hospital Department of Nephrology

kiyo.0817.piyo@iuhw.ac.jp+81-476-35-5600

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026